SCM
XENE icon

Sterling Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Sterling Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.8K Sell
345
-215
-38% -$11.9K ﹤0.01% 1868
2026
Q1 		$32.6K Buy
560
+69
+14% +$3.18K ﹤0.01% 1813
2025
Q4 		$22K Buy
491
+307
+167% +$12.9K ﹤0.01% 2177
2025
Q3 		$7.39K Hold
184
– – ﹤0.01% 2637
2025
Q2 		$5.76K Buy
+184
New +$6K ﹤0.01% 2433

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Sterling Capital Management's XENE Position: Q2 2026 in Review

Sterling Capital Management reduced its Xenon Pharmaceuticals (XENE) stake by 38% in Q2 2026, selling an estimated $11.9K and leaving 345 shares worth $20.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1868.

Sterling Capital Management first reported a position in XENE in Q2 2025 and has held it in 5 quarters since. The position peaked at $32.6K in Q1 2026. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Sterling Capital Management held 345 shares of Xenon Pharmaceuticals worth $20.8K as of Q2 2026.
  • Sterling Capital Management sold 215 Xenon Pharmaceuticals shares in Q2 2026, an estimated $11.9K.
  • Xenon Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1868 holding.
  • Sterling Capital Management first reported a position in Xenon Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Sterling Capital Management's Xenon Pharmaceuticals position peaked at $32.6K in Q1 2026.
  • 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.